Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 8/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 6/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15859958 | 0.90 | MAP3K20 (0.48) | ABL1MAPK14MAP3K20SRCEGFR | |
| SCHEMBL17324209 | 0.83 | EGFR (0.46) | ABL1SRCEGFRBRAF | |
| SCHEMBL17426706 | 0.81 | CHRM3 (0.46) | CHRM3ROCK1ROCK2ABL1EGFR | |
| SCHEMBL15860121 | 0.80 | MAP3K20 (0.59) | ABL1MAPK14MAP3K20EGFRBRAF | |
| SCHEMBL15847641 | 0.79 | EGFR (0.54) | ABL1MAPK14MAP3K20SRCEGFR | |
| SCHEMBL15859948 | 0.76 | EGFR (0.56) | ABL1MAPK14MAP3K20EGFRBRAF | |
| SCHEMBL15860029 | 0.75 | KIT (0.51) | ABL1MAPK14MAP3K20SRCEGFR | |
| SCHEMBL17324215 | 0.75 | ABL1 (0.46) | ABL1SRCEGFRBRAF | |
| SCHEMBL15860000 | 0.74 | BRAF (0.58) | ABL1MAPK14MAP3K20EGFRBRAF | |
| SCHEMBL15859875 | 0.74 | ABL1 (0.56) | ABL1MAPK14MAP3K20SRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | MAP2K2, MAP2K5, MAP2K3 | CHRM3 3660/4885HTR2C 2457/4885MCHR1 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.